Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
While slower gut motility is a well-established risk factor for bacterial overgrowth, it does not guarantee that you will develop SIBO, IMO, or related conditions
These conventional strategies face significant obstacles: Most medications used for tinnitussuch as antidepressants, anticonvulsants, or anxiolyticsonly manage comorbid symptoms like anxiety and depression, without addressing underlying auditory dysfunction
Based on the current stage of clinical development and estimated trial completion dates registered on ClinicalTrials.gov, a realistic earliest possible timeline might be considered as follows: 20252026: Completion of key phase 3 TRIUMPH trial data 20262027: Potential regulatory submission to the MHRA (and FDA/EMA in parallel) 20272028: Possible MHRA marketing authorisation, subject to satisfactory review 2028 onwards: NICE technology appraisal and potential NHS commissioning decision These timelines are speculative and depend on multiple variables, including trial outcomes, the completeness of the regulatory submission, MHRA review timelines, and NICE deliberations
First posted October 2025
01 Is PinPoint medical advice
